Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
CENTOCOR, INC.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Subsidiary
Employees
1.2K
Market Cap
-
Website
http://www.centocor.com
Clinical Trials
Related News
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: CNTO 328 (Sp2/0-derived)
Drug: CNTO 328 (CHO-derived)
Drug: Placebo
Subscribe
First Posted Date
2014-02-28
Last Posted Date
2015-02-05
Lead Sponsor
Centocor, Inc.
Target Recruit Count
145
Registration Number
NCT02074800
Subscribe
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)
Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Golimumab
Subscribe
First Posted Date
2011-05-30
Last Posted Date
2017-10-02
Lead Sponsor
Centocor, Inc.
Target Recruit Count
49
Registration Number
NCT01362153
Subscribe
A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects
Phase 1
Completed
Conditions
Healthy Adult Chinese Males
Interventions
Drug: Golimumab
Subscribe
First Posted Date
2011-02-02
Last Posted Date
2014-05-28
Lead Sponsor
Centocor, Inc.
Target Recruit Count
24
Registration Number
NCT01288157
Subscribe
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 3
Withdrawn
Conditions
Multiple Myeloma
Interventions
Biological: Siltuximab, Velcade and dexamethasone
Drug: Placebo, Velcade and dexamethasone
Subscribe
First Posted Date
2010-12-24
Last Posted Date
2013-01-28
Lead Sponsor
Centocor, Inc.
Registration Number
NCT01266811
Subscribe
A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects
Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: 200 mg golimumab or placebo
Drug: 400 mg golimumab or placebo
Subscribe
First Posted Date
2010-12-13
Last Posted Date
2013-09-04
Lead Sponsor
Centocor, Inc.
Target Recruit Count
49
Registration Number
NCT01258777
Subscribe
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis
Phase 3
Completed
Conditions
Ankylosing Spondylitis
Interventions
Drug: Placebo
Drug: Golimumab
Drug: Golimumab (placebo group)
Subscribe
First Posted Date
2010-11-25
Last Posted Date
2013-03-20
Lead Sponsor
Centocor, Inc.
Target Recruit Count
213
Registration Number
NCT01248793
Subscribe
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: Golimumab
Drug: Methotrexate (MTX)
Subscribe
First Posted Date
2010-11-25
Last Posted Date
2013-09-06
Lead Sponsor
Centocor, Inc.
Target Recruit Count
264
Registration Number
NCT01248780
Subscribe
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Phase 1
Completed
Conditions
Cancer
Interventions
Drug: CNTO888 + docetaxel
Drug: CNTO888 + gemcitabine
Drug: CNTO888 + Paclitaxel and carboplatin
Drug: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
Subscribe
First Posted Date
2010-09-20
Last Posted Date
2012-05-30
Lead Sponsor
Centocor, Inc.
Target Recruit Count
53
Registration Number
NCT01204996
Subscribe
A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma
Phase 1
Completed
Conditions
Asthma
Interventions
Biological: CNTO 3157 or placebo
Subscribe
First Posted Date
2010-09-06
Last Posted Date
2012-11-27
Lead Sponsor
Centocor, Inc.
Target Recruit Count
79
Registration Number
NCT01195207
Subscribe
A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers
Phase 1
Completed
Conditions
Healthy
Interventions
Biological: CNTO 5825
Subscribe
First Posted Date
2010-03-05
Last Posted Date
2010-10-01
Lead Sponsor
Centocor, Inc.
Target Recruit Count
64
Registration Number
NCT01081691
Subscribe
Prev
1
2
3
4
5
8
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy